Related references
Note: Only part of the references are listed.Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL
Sonia Rodriguez et al.
LEUKEMIA (2020)
Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments
Haoyu Zou et al.
HUMAN GENE THERAPY (2020)
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia
Diego Sanchez-Martinez et al.
BLOOD (2019)
Chimeric Antigen Receptors for T-Cell Malignancies
Lauren D. Scherer et al.
FRONTIERS IN ONCOLOGY (2019)
Chimeric antigen receptor T cell persistence and memory cell formation
Alexander D. McLellan et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Olivia C. Finney et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives
Mohamad Mohty et al.
LEUKEMIA (2019)
Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies
Mathew L. Cooper et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
Sophia Stock et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia
Diogo Gomes-Silva et al.
MOLECULAR THERAPY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions
Lauren C. Fleischer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers
Rajat K. Das et al.
CANCER DISCOVERY (2019)
T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies
Eduardo Vadillo et al.
BLOOD REVIEWS (2018)
T cell senescence and CAR-T cell exhaustion in hematological malignancies
Dimitri Kasakovski et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
An off-the-shelf fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Matthew L. Cooper et al.
LEUKEMIA (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments
Michelle L. Kimberland et al.
JOURNAL OF BIOTECHNOLOGY (2018)
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
Stephanie Vairy et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies
Yi Tian Png et al.
BLOOD ADVANCES (2017)
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Diogo Gomes-Silva et al.
BLOOD (2017)
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Marianna Sabatino et al.
BLOOD (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases
Shengdar Q. Tsai et al.
NATURE REVIEWS GENETICS (2016)
The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Laura Belver et al.
NATURE REVIEWS CANCER (2016)
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Maksim Mamonkin et al.
BLOOD (2015)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
Xin Yao et al.
BLOOD (2012)
Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?
Christopher A. Klebanoff et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
A multi-Fc-species system for recombinant antibody production
Sandrine Moutel et al.
BMC BIOTECHNOLOGY (2009)
Activated T-cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma
Keichiro Mihara et al.
JOURNAL OF IMMUNOTHERAPY (2009)
T cell signal transduction and the role of CD7 in costimulation
R Stillwell et al.
IMMUNOLOGIC RESEARCH (2001)